NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success as it mission. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of raw human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.
NuMedii is initially using its Big Data technology to discover and de-risk new indications for safe, existing drugs. It plans to apply the same approach to discover and de-risk new molecular entities based on therapeutically relevant biological networks.